TSE:4536 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TSE:4536 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Santen Pharmaceutical Co has a Altman Z2-Score of 7.23, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Santen Pharmaceutical Co's Altman Z2-Score or its related term are showing as below:
During the past 13 years, Santen Pharmaceutical Co's highest Altman Z2-Score was 10.06. The lowest was 6.13. And the median was 7.82.
The historical data trend for Santen Pharmaceutical Co's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co Annual Data | |||||||||||||||||||||
Trend | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | |||||||||||
Altman Z2-Score | Get a 7-Day Free Trial | 8.16 | 7.89 | 7.38 | 6.13 | 6.93 |
Santen Pharmaceutical Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Altman Z2-Score | Get a 7-Day Free Trial | 7.30 | 7.04 | 6.93 | - | 7.23 |
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Santen Pharmaceutical Co's Altman Z2-Score for today is calculated with this formula:
Z | = | 6.56 | * | X1 | + | 3.26 | * | X2 | + | 6.72 | * | X3 | + | 1.05 | * | X4_2 |
= | 6.56 | * | 0.3291 | + | 3.26 | * | 0.6183 | + | 6.72 | * | 0.0808 | + | 1.05 | * | 2.3916 | |
= | 7.23 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was 円409,085 Mil.
Total Current Assets was 円218,478 Mil.
Total Current Liabilities was 円83,868 Mil.
Retained Earnings was 円252,938 Mil.
Pre-Tax Income was 10389 + 13450 + -3685 + 9484 = 円29,638 Mil.
Interest Expense was -636 + -407 + -1683 + -703 = 円-3,429 Mil.
Total Liabilities was 円120,831 Mil.
* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.
X1 | = | Working Capital | / | Total Assets |
= | (Total Current Assets - Total Current Liabilities) | / | Total Assets | |
= | (218478 - 83868) | / | 409085 | |
= | 0.3291 |
X2 | = | Retained Earnings | / | Total Assets |
= | 252938 | / | 409085 | |
= | 0.6183 |
X3 | = | Earnings Before Interest and Taxes | / | Total Assets |
= | (Pre-Tax Income - Interest Expense) | / | Total Assets | |
= | (29638 - -3429) | / | 409085 | |
= | 0.0808 |
X4_2 | = | Net Worth | / | Total Liabilities |
= | (Total Stockholders Equity - Preferred Stock) | / | Total Liabilities | |
= | (288977 - 0) | / | 120831 | |
= | 2.3916 |
The zones of discrimination were as such:
Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones
Santen Pharmaceutical Co has a Altman Z2-Score of 7.23 indicating it is in Safe Zones.
Santen Pharmaceutical Co (TSE:4536) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.
Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.
Be Aware
Altman Z2-Score does not apply to financial companies.
Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.